deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT02258867

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis (EYEGUARD™-US)

A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis

Sponsor: XOMA (US) LLC

Conditions Behcet's Disease Uveitis
Interventions Gevokizumab Placebo
Updated 6 times since 2017 Last updated: Dec 28, 2015 Started: Nov 30, 2014 Primary completion: Oct 31, 2015 Completion: Nov 30, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from XOMA (US) LLC

More terminations from XOMA (US) LLC

Listed as NCT02258867, this PHASE3 trial focuses on Behcet's Disease Uveitis and remains terminated or withdrawn. Sponsored by XOMA (US) LLC, it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE3

    First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • XOMA (US) LLC
Data source: XOMA (US) LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations